Role and therapeutic targeting of glutamine metabolism in non-small cell lung cancer (Review)

被引:2
|
作者
Zhou, Lei [1 ]
Zhang, Qi [2 ]
Zhu, Qing [2 ]
Zhan, Yuan [3 ]
Li, Yong [4 ,5 ]
Huang, Xuan [2 ,6 ]
机构
[1] Nanchang Univ, Clin Med Coll 1, Nanchang 330036, Jiangxi, Peoples R China
[2] Nanchang Univ, Inst Translat Med, Natl Engn Res Ctr Bioengn Drugs & Technol, Nanchang 330036, Jiangxi, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Dept Pathol, Nanchang 330006, Jiangxi, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 1, Med Ctr Anesthesiol & Pain, Dept Anesthesiol, Nanchang 330006, Jiangxi, Peoples R China
[5] Nanchang Univ, Med Ctr Anesthesiol & Pain, Dept Anesthesiol, Affiliated Hosp 1, 17 Yongwai St, Nanchang 330006, Jiangxi, Peoples R China
[6] Nanchang Univ, Inst Translat Med, Natl Engn Res Ctr Bioengn Drugs & Technol, 1299 Xuefu Rd, Nanchang 330036, Jiangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
non-small cell lung cancer; glutamine metabolism; therapeutic strategies; Warburg effect; metabolism inhibitor; ANTITUMOR-ACTIVITY; GROWTH; INHIBITION; BIOLOGY; GLUTATHIONE; PATHWAYS; EGFR; CLASSIFICATION; PROLIFERATION; SUPPRESSION;
D O I
10.3892/ol.2023.13745
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Warburg effect indicates that cancer cells survive through glycolysis under aerobic conditions; as such, the topic of cancer metabolism has aroused interest. It is requisite to further explore cancer metabolism, as it helps to simultaneously explain the process of carcinogenesis and guide therapy. The flexible metabolism of cancer cells, which is the result of metabolic reprogramming, can meet the basic needs of cells, even in a nutrition-deficient environment. Glutamine is the most abundant non-essential amino acid in the circulation, and along with glucose, comprise the two basic nutrients of cancer cell metabolism. Glutamine is crucial in non-small cell lung cancer (NSCLC) cells and serves an important role in supporting cell growth, activating signal transduction and maintaining redox homeostasis. In this perspective, the present review aims to provide a new therapeutic strategy of NSCLC through inhibiting the metabolism of glutamine. This review not only summarizes the significance of glutamine metabolism in NSCLC cells, but also enumerates traditional glutamine inhibitors along with new targets. It also puts forward the concept of combination therapy and patient stratification with the aim of comprehensively showing the effect and prospect of targeted glutamine metabolism in NSCLC therapy. This review was completed by searching for keywords including 'glutamine', 'NSCLC' and 'therapy' on PubMed, and screening out articles.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Targeting BRAF mutations in non-small cell lung cancer
    O'Leary, Connor Gerard
    Andelkovic, Vladamir
    Ladwa, Rahul
    Pavlakis, Nick
    Zhou, Caicun
    Hirsch, Fred
    Richard, Derek
    O'Byrne, Kenneth
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (06) : 1119 - 1124
  • [22] Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer
    Lammers, Philip E.
    Horn, Leora
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (10): : 1235 - 1247
  • [23] Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer
    Bilal Piperdi
    Amartej Merla
    Roman Perez-Soler
    Drugs, 2014, 74 : 403 - 413
  • [24] Targeting estrogen signaling pathways for therapeutic intervention in non-small cell lung cancer.
    Marquez, Diana C.
    Mah, Vei
    Goodglick, Lee
    Garbon, Hermes
    Weinberg, Olga
    Fishbein, Michael
    Chia, David
    Chen, Hsiao-Wang
    Dubinett, Steven
    Seligson, David
    Pietras, Richard
    CANCER RESEARCH, 2006, 66 (08)
  • [25] Proteolysis targeting chimeras in non-small cell lung cancer
    Hagopian, Garo
    Grant, Christopher
    Nagasaka, Misako
    CANCER TREATMENT REVIEWS, 2023, 117
  • [26] Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer
    Piperdi, Bilal
    Merla, Amartej
    Perez-Soler, Roman
    DRUGS, 2014, 74 (04) : 403 - 413
  • [27] Targeting RET alterations in non-small cell lung cancer
    Nishikawa, Go
    Klein, Mark A.
    CURRENT PROBLEMS IN CANCER, 2024, 49
  • [28] Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
    Desage, Anne-Laure
    Leonce, Camille
    Swalduz, Aurelie
    Ortiz-Cuaran, Sandra
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
    Al Khatib, Arwa Omar
    El-Tanani, Mohamed
    Al-Obaidi, Hisham
    PHARMACEUTICS, 2023, 15 (12)
  • [30] Targeting driver mutations in non-small cell lung cancer
    Vreka, Malamati
    Stathopoulos, Georgios T.
    Marazioti, Antonia
    PNEUMON, 2015, 28 (02) : 130 - 132